Treatment of overweight and obese girls experiencing central precocious puberty: a comparison of the effectiveness of leuprolide acetate and triptorelin pamoate
Authors:
- Thanaporn ThaneetrakoolTTThanaporn Thaneetrakool
- Suphab AroonparkmongkolSASuphab Aroonparkmongkol
- Krittamate ChatdamrongsakoolKCKrittamate Chatdamrongsakool
- Nattakarn NumsriskulratNNNattakarn Numsriskulrat
- Vichit SupornsilchaiVSVichit Supornsilchai
- Suttipong WacharasindhuSWSuttipong Wacharasindhu
- Khomsak SrilanchakonKSKhomsak Srilanchakon
Open Access
- 31 August 2025
- journal article
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 30 (4) , 207-212
Abstract
Purpose: Gonadotropin-releasing hormone agonists are the standard treatment for central precocious puberty (CPP). These agonists include leuprolide acetate and triptorelin pamoate, but research data for the relative effectiveness of these 2 treatments in overweight and obese girls experiencing CPP are lacking. In this study, we compared the effectiveness of these 2 therapeutics, leuprolide acetate and triptorelin pamoate, in the treatment of overweight and obese girls affected by CPP.Methods: We enrolled 69 overweight and obese girls with CPP in this retrospective cohort study and classified these participants according to their baseline body mass index (BMI) status, BMI≥1 standard deviation scoer. Leuprolide acetate was administered to 48 of the participants, and the other 21 were treated with triptorelin pamoate. The anthropometric measurements were compared at the beginning and conclusion of the therapy, and luteinizing hormone (LH) suppression levels were assessed 6 months following the completion of treatment.Results: Leuprolide acetate and triptorelin pamoate substantially suppressed LH when administered to overweight and obese girls with CPP. The predicted adult height (PAH) at the conclusion of treatment was comparable between the 2 groups.Conclusion: There was no significant difference in the level of LH suppression and PAH between the 2 groups, overweight and obese girls with CPP treated with leuprolide acetate and those treated with triptorelin pamoate.Keywords
This publication has 23 references indexed in Scilit:
- Efficacy and Safety of Triptorelin 3-Month Formulation in Chinese Children with Central Precocious Puberty: A Phase 3, Open-Label, Single-Arm StudyAdvances in Therapy, 2023
- Efficacy of Leuprorelin 3-Month Depot (11.25 mg) Compared to 1-Month Depot (3.75 mg) for Central Precocious Puberty in Chinese Girls: A Prospective Cohort StudyInternational Journal of Endocrinology, 2022
- Long‐term efficacy and safety of gonadotropin‐releasing hormone analog treatment in children with idiopathic central precocious puberty: A systematic review and meta‐analysisClinical Endocrinology, 2021
- Central precocious puberty, functional and tumor-relatedBest Practice & Research Clinical Endocrinology & Metabolism, 2019
- Meta-Analysis of Paediatric Patients with Central Precocious Puberty Treated with Intramuscular Triptorelin 11.25 mg 3-Month Prolonged-Release FormulationHormone Research in Paediatrics, 2017
- A 6-Month Trial of the Efficacy and Safety of Triptorelin Pamoate (11.25 mg) Every 3 Months in Children with Precocious Puberty: A Retrospective Comparison with Triptorelin AcetateHormone Research in Paediatrics, 2016
- Causes, diagnosis, and treatment of central precocious pubertyThe Lancet Diabetes & Endocrinology, 2016
- Assessment of Estradiol Response after Depot Triptorelin Administration in Girls with Central Precocious PubertyHormone Research in Paediatrics, 2015
- Long-term impact of overweight and obesity in childhood and adolescence on morbidity and premature mortality in adulthood: systematic reviewInternational Journal of Obesity, 2010
- Precocious PubertyNew England Journal of Medicine, 2008